Want to see VNDA full AI Analyst Report?
VNDA Stock Chart & Stats
$5.18
$0.12(2.32%)
At close: 4:00 PM EDT
$5.18
$0.12(2.32%)
Day’s Range― - ―
52-Week Range$4.15 - $9.94
Previous CloseN/A
Volume13.12K
Average Volume (3M)881.91K
Market Cap
$306.69M
Enterprise Value$221.29
Total Cash (Recent Filing)$170.03M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 04, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.63
Shares Outstanding60,135,563
10 Day Avg. Volume910,563
30 Day Avg. Volume881,909
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.59
Price to Sales (P/S)2.41
P/FCF Ratio-4.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.33Price Target Upside215.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$262.10M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVanda's minimal debt and low leverage provide durable financial flexibility, reducing refinancing and solvency risk. This structural strength supports funding of launches and late‑stage trials from existing resources or modest capital markets access, lengthening runway versus highly levered peers.
BYSANTI Approval With Long ExclusivityBYSANTI's FDA approval plus multi‑year data exclusivity and long patent life create a structurally protected revenue stream. This long runway for exclusivity supports predictable pricing and market share build, making BYSANTI a durable contributor to commercial revenue if uptake and payer coverage materialize.
Sustained Fanapt Commercial MomentumRobust, repeatable prescription growth and rising net sales indicate durable physician adoption and commercial execution. Sustained Fanapt traction across expanded indications builds an ongoing revenue base that can help finance launches and offset declines elsewhere if the company maintains commercialization effectiveness.
Bears Say
Rising Cash Burn And Shrinking Cash BalanceRapid cash depletion and higher projected 2026 burn create a persistent financing overhang. If launches, trial readouts or near‑term revenues underperform, the company may need to raise capital or cut spending, increasing dilution risk and constraining long‑term R&D and commercial investments essential to growth.
TTM Revenue Collapse And Margin DeteriorationA persistent top‑line decline and sharply worsened margins materially weaken internal cash generation and have eroded shareholders' equity. This structural profitability erosion reduces reinvestment capacity, elevates reliance on external funding, and lengthens the path to sustainable earnings unless product performance reverses.
Legacy Erosion And Launch Demand UncertaintyGeneric competition has materially impaired legacy HETLIOZ cash flows, while constrained recognition of NEREUS inventory and wholesaler return risk make new product revenue unreliable. Combined, these structural headwinds increase revenue volatility and complicate forecasting and funding for ongoing programs.
Vanda News
VNDA FAQ
What was Vanda Pharmaceuticals’s price range in the past 12 months?
Vanda Pharmaceuticals lowest stock price was $4.15 and its highest was $9.94 in the past 12 months.
What is Vanda Pharmaceuticals’s market cap?
Vanda Pharmaceuticals’s market cap is $306.69M.
When is Vanda Pharmaceuticals’s upcoming earnings report date?
Vanda Pharmaceuticals’s upcoming earnings report date is Nov 04, 2026 which is in 87 days.
How were Vanda Pharmaceuticals’s earnings last quarter?
Vanda Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.582 by -$0.458.
Is Vanda Pharmaceuticals overvalued?
According to Wall Street analysts Vanda Pharmaceuticals’s price is currently Undervalued.
Does Vanda Pharmaceuticals pay dividends?
Vanda Pharmaceuticals does not currently pay dividends.
What is Vanda Pharmaceuticals’s EPS estimate?
Vanda Pharmaceuticals’s EPS estimate is -0.61.
How many shares outstanding does Vanda Pharmaceuticals have?
Vanda Pharmaceuticals has 60,135,563 shares outstanding.
What happened to Vanda Pharmaceuticals’s price movement after its last earnings report?
Vanda Pharmaceuticals reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.582. Following the earnings report the stock price went up 0.491%.
Which hedge fund is a major shareholder of Vanda Pharmaceuticals?
Currently, no hedge funds are holding shares in VNDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vanda Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (215.32% Upside)
$16.33 (215.32% Upside)
Blogger Sentiment
Bullish
VNDA Sentiment 91%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 206.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.40%
Trailing 12-Months
Company Description
Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
VNDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: multiple commercial and regulatory positives (strong Fanapt momentum, BYSANTI approval, NEREUS launch, imsidolimab BLA under review, several near-term phase 3 readouts, and reiterated 2026 revenue guidance implying growth) balanced against significant near-term financial pressures (larger net losses, sharply lower HETLIOZ sales due to generics, constrained NEREUS revenue recognition, increased operating expenses and reduced cash vs year-end 2025). Management expects operating expense moderation later in 2026 and into 2027 and believes existing resources plus anticipated revenues will fund operations through at least end of 2027, but execution risk on launches, trial readouts and revenue realization remain key uncertainties.View all VNDA earnings summariesVNDA Stock 12 Month Forecast
Average Price Target
$16.33
▲(215.32% Upside)
Technical Analysis
Ownership Overview
8.85% Insiders
13.94% Mutual Funds
4.17% Other Institutional Investors
55.66% Public Companies and
Individual Investors